/
ORKA
$110.21+$2.09 (+1.93%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$7.1B
66M shares
52-week range
$14.08 – $110.64
100% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change+$84.71
Oruka Therapeutics, Inc. Common Stock
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
www.orukatx.com- Employees
- 68
- IPO / List date
- Sep 3, 2024
- HQ
- MENLO PARK, CA
Held by traders on TradeandTell
No one on the platform currently holds ORKA.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-06-30 | 13,900 | $155.8K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ORKA yet.
